Mark Rose, Ph.D., is Vice President of Drug Metabolism and Pharmacokinetics (DMPK) and Non-clinical Safety. He has over 25 years of experience in all aspects of pharmaceutical development, from early discovery to late-stage clinical testing. Mark brings expertise in preclinical characterization, including pharmacokinetics, PK modeling, biomarker identification, GLP toxicology testing, bioanalysis, and IND writing and support, and has managed preclinical regulatory submissions for a diverse portfolio of research projects. Most recently, Mark was Vice President of DMPK at DTx Pharma (acquired by Novartis). Before that, he served as Executive Director and Head of DMPK at Gossamer Bio, Inc., Director of DMPK at CHDI Management, Inc., Director of DMPK at Amgen Inc., and as a Research Fellow in the Department of Drug Metabolism at Merck Research Laboratories. Dr. Rose has co-authored over 100 publications and presented abstracts in analytical chemistry, bioanalysis, drug discovery, and pharmacokinetics. He received a B.S. in Chemistry from Pennsylvania State University and a Ph.D. in Pharmaceutical Chemistry from the University of Kansas.